Locametz (kit for Ga-68 gozetotide)
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
Overview
Locametz was approved by the FDA on 23 March 2022, alongside Pluvicto (lutetium-177 vipivotide tetraxetan), with an explicit indication for selecting patients with metastatic castration-resistant prostate cancer for PSMA-directed therapy, as well as for initial staging and biochemical recurrence. The European Commission approved it in December 2022. It is manufactured by Advanced Accelerator Applications, the Novartis radiopharmaceutical unit, and was the first PSMA PET agent approved in the EU. The scan-then-treat pairing is the template for theranostics.
- Detector ring
- PSMA ligand
- 511 keV photon pair
Kit for on-site labelling of gozetotide (PSMA-11) with gallium-68; the resulting tracer images PSMA-expressing prostate cancer and identifies candidates for lutetium-177 PSMA therapy. Connects to PSMA.
- PSMA / SSTR-positive cell
1.Locametz (kit for Ga-68 gozetotide) slips into a pocket on PSMA.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2022 | PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy |
| EU | 2022 | PSMA PET in prostate cancer |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Notes
top- What a result means: enough PSMA uptake on the scan is required before Pluvicto can be given; a scan without uptake means the drug is unlikely to work.
Latest papers
topQuery for this drug: (TITLE:"Locametz" OR ABSTRACT:"Locametz" OR TITLE:"kit for Ga-68 gozetotide" OR ABSTRACT:"kit for Ga-68 gozetotide") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Locametz (kit for Ga-68 gozetotide), not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentFludeoxyglucose F-18 (FDG)
Shares PET/CT and the tag test.
- Key paperVISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, VISION, Theranostics, Novartis.
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Gallium-68.
- PersonMichael J. Morris
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, VISION, PSMA, Lutetium-177 vipivotide tetraxetan.
- PersonThomas A. Hope
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, PSMA PET, Gallium-68.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- TermPSMA-RADS (PSMA reporting and data system)
Shares Gallium-68 gozetotide (PSMA-11), VISION, PSMA, Lutetium-177 vipivotide tetraxetan.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET.